All Topics
All Topics
Technology
Technology
Design
Design
Programming
Programming
Science
Science
News
News
Gaming
Gaming
Entertainment
Entertainment
Business
Business
Finance
Finance
Sports
Sports
Health
Health
Food
Food
Travel
Travel
Art
Art
Music
Music
Books
Books
Education
Education
Politics
Politics
Personal
Personal
No algorithm. No AI slop. No ads. Just RSS. Pro-human. Indie writers. Real journalism. Open web. Chronological. Hand toasted.

Phase III trial finds EpiWatch smartwatch app detects tonic-clonic seizures with 98% accuracy

By

Dr. Liji Thomas, MD

1h ago· 7 min readenNews

Summary

A Phase III clinical trial of the FDA-cleared EpiWatch smartwatch app demonstrated 98% accuracy in detecting tonic-clonic seizures in children and adults, with a low false alarm rate of approximately one every 12 days. The app addresses a major challenge in wearable epilepsy monitoring and could help reduce the risk of Sudden Unexpected Death in Epilepsy (SUDEP) by providing timely alerts to caregivers.

Key quotes

· 3 pulled
An FDA-cleared smartwatch app detected nearly every tonic-clonic seizure in a Phase III trial while producing just one false alarm every 12 days
A Phase III clinical trial evaluating the effectiveness of the smartwatch-based app EpiWatch concluded that it could detect tonic-clonic seizures (TCS) relatively early and had a low false alarm rate (FAR)
The EpiWatch app shows high sensitivity in detecting tonic-clonic seizures in children and adults, potentially reducing SUDEP risk with timely alerts
Snippet from the RSS feed
The EpiWatch app shows high sensitivity in detecting tonic-clonic seizures in children and adults, potentially reducing SUDEP risk with timely alerts.

You might also wanna read